We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Final page and here's the link: https://www.has-sante.fr/jcms/p_3213598/en/avis-n-2020-0062/ac/seap-du-15-octobre-2020-du-college-de-la-haute-autorite-de-sante-relatif-a-l-inscription-sur-la-liste-des-actes-et-prestations-mentionnee-a-l-article-l-162-1-7-du-code-de-la-securite-sociale-de-la-recherche-directe-des-virus-des-infections-respiratoires-hivernales-dont-les-virus-influenza-a-et-b-concomitamment-a-la-recherche-directe-du-virus-sars-cov-2-sur-prelevement-nasopharynge-en-periode-de-co-circulation-de-ces-virus
the usefulness of influenza vaccination in priority for people at risk of severe influenza;
the importance of respecting barrier gestures in the fight against the spread of these two viruses;
that these present conclusions will be reviewed in the light of scientific, technological and epidemiological developments relating to these infections.
1 / Adult symptomatic patients.
1a / Patients in hospitals (emergencies and hospitalization) showing symptoms of a respiratory infection, likely to have an influenza or other viral origin and / or COVID-19.
Search for the RNA of viruses responsible for winter respiratory infection (including influenza A and B viruses) by reverse transcriptase and polymerase chain reaction (reverse transcriptase - polymerase chain reaction, or RT-PCR) on nasopharyngeal sample.
Search for SARS-CoV-2 RNA by gene amplification on nasopharyngeal sample.
This research can be carried out using:
multiplex tests detecting the genomes of all viruses responsible for winter respiratory infections (including influenza) and SARS-CoV-2;
or multiplex tests detecting the genomes of all viruses responsible for winter respiratory infections (including influenza) and another unit test detecting the genome of SARS-CoV-2;
or failing this and at a minimum, two unit tests or a duplex test detecting the genomes of SARS-CoV-2 and influenza A and B viruses.
It is recalled that a SARS-CoV-2 antigen test can also be used in emergencies.
1b / Patients residing in residential establishments for dependent elderly people, or other medico-social establishments presenting symptoms likely to have an influenza and / or COVID-19 origin but whose condition does not require a transfer to the hospital.
If a SARS-CoV-2 antigen test is performed on a nasopharyngeal swab, this can be followed:
in the event of a positive antigenic test, by searching for influenza virus RNA by RT-PCR on a nasopharyngeal sample;
in the event of a negative antigenic test, by testing for influenza virus RNA and SARS-CoV-2 by gene amplification on a nasopharyngeal sample, either by two unit tests or a duplex test.
The search for the RNA of influenza viruses and SARS-CoV-2 by gene amplification on a nasopharyngeal sample can also be performed straight away.
2 / Child patients presenting symptoms of a respiratory infection, likely to have an influenza and / or COVID-19 origin.
2a / Patients in hospitals (emergencies and hospitalization).
The tests and their performance methods are the same as for symptomatic adult patients treated in a healthcare establishment, taking into account the specific measures linked to respiratory syncitial virus (RSV) infection.
2b / Patients residing in medico-social establishments whose condition does not require a transfer to the hospital.
Search for antigenic proteins of influenza viruses and SARS-CoV-2 (antigenic tests).
2c / Patients examined in town.
Search for antigenic proteins of influenza viruses and SARS-CoV-2 (antigenic tests).
The search for influenza virus antigen is ideally carried out at the point of care by immunochromatography (Rapid Diagnostic Orientation Test), otherwise in the medical biology laboratory by assay of immuno-absorption by linked enzyme (enzyme linked immunosorbent assay). , or ELISA).
HAS OPINIONS AND DECISIONS - Posted on Oct 21 2020
Taking into account the following background elements: in mainland France, a co-circulation of SARS-CoV-2 responsible for COVID-19 and certain viruses responsible for winter respiratory infections has started. Among these winter viruses, influenza A and B viruses responsible for influenza are particularly monitored given the risks of severe influenza and death in patients at risk; the clinical signs of influenza and COVID-19 are very similar and no symptom or clinical picture is really specific to one or the other; it is then very difficult to make a differential diagnosis of these two infections on the sole clinical examination, while cases of co-infections have been described; people at risk of severe forms of one or the other of these two viral infections are generally the same (elderly people, patients with chronic diseases, etc.); the possible consequences of co-infection of Influenza A / B and SARS-CoV-2 viruses on mortality; various direct search examinations for the SARS-CoV-2 virus are already available and covered by the Health Insurance, under conditions set by decrees of the Minister of Solidarity and Health, taken after opinion of the High Health authority; research into the genomes of the different viruses is aimed at (i) reducing the rate of hospital admission for emergency patients, (ii) organizing separate isolation measures for patients hospitalized or accommodated in medico-social establishments and carriers of influenza and / or SARS-CoV-2 viruses (in order to avoid the transmission of infection and co-infections) and (iii) to set up optimal diagnostic management (orientations / limitations of complementary explorations) and therapeutic (in particular a correct prescription of antibiotics);
There is no curative antiviral treatment against these two infections having demonstrated sufficient medical benefit;
The use of different tests is independent of the patient's vaccination status.
After carrying out a general review of the literature - including in particular the opinion of the High Council for Public Health of September 17, 2020 relating to the co-circulation of SARS-CoV-2 and winter viruses as well as the rapid response of the '' National Institute of Excellence in Health and Social Services of Quebec on October 7, 2020 and interviewed a group of experts composed of medical biologist (virologist), clinician (general practitioner, pediatrician, geriatrician and infectious disease specialist) and patient, selected After consulting the HAS ethics committee, the Haute Autorité de santé specifies the possible uses of the various tests (this is not a strategy recommendation):
Continues.......
New jobs on offer are now 12 Month contracts up from 6. See gggg21 on Twitter
Welcome EXMEX, thanks for finding it!!
Airlineboy, thanks for getting that link to work.
Actually it mentions Multiplex NOT Winterplex
Is Winterplex trade marked to us? It gets a specific mention here https://www.has-sante.fr/jcms/p_3213581/en/distinguer-la-grippe-de-la-covid-19-dans-quelles-situations-et-avec-quels-tests
PRESS RELEASE - Posted on Oct 21 2020
October 21, 2020
In recent weeks, the HAS has established the strategy for using the various diagnostic tests for COVID-19. In a period of co-circulation of different viruses (SARS-CoV-2 but also influenza viruses and other respiratory viruses), she is now interested in what will allow health professionals to distinguish them. It thus defines the indications of combined tests, useful when the result impacts the management of the patient and his possible isolation.
The start of autumn marks the return of winter respiratory infections, the symptoms of which - not very specific - sometimes resemble those of COVID-19 (fever, stuffy nose, headaches, etc.). Among them, influenza, which can progress to serious forms in some populations. To make a diagnosis, it is possible to perform several unit tests carried out simultaneously or to use a so-called "multiplex" test. As a reminder, a multiplex test makes it possible to simultaneously detect several infectious agents (viruses, bacteria) from the same sample and with the same gene amplification technique, usually of the PCR type.
The HAS considers that there is an interest in looking for one or more viruses of winter respiratory infections (including influenza) in association with a search for SARS-CoV-2 in only patients who present symptoms and for whom the result will be useful for determining the nature of the care and / or a particular isolation: adults hospitalized or arriving in emergencies, residents in EHPAD and young children. In other people, the identification of the winter virus virus does not have any consequences on the management which is based on the treatment of the symptoms and the monitoring of the evolution of the disease, the use of these tests is unnecessary. . Only a detection test for SARS-CoV-2 is then indicated
For some reason our multiplex test is under 'RT PCR Simple' instead of 'RT PCR Multiplex' - Second dropdown options. I am not sure if this is a mistake or...
See if this link works
https://www.has-sante.fr/jcms/fc_2874839/en/presse
https://covid-19.sante.gouv.fr/tests about a third of the way down the list you will see two of our tests listed here
Coronavirus (COVID-19) genesig Real-time PCR
Primerdesign NOVACYT SERVIBIO Simple RT PCR Coronavirus (COVID-19) genesig Real-time PCR
Primerdesign NOVACYT ATOTHIS Simple RT PCR
Coronavirus (COVID-19) genesig Real-time PCR
General informations
Type of test
Gene amplification
Test subtype
Simple RT PCR
Maker Primerdesign NOVACYT
Distributor name
ATOTHIS
CE marking Yes
HAS compliance No
CNR assessment Favorable opinion
I see the Haute Sante have finally released their ruling on multiplex tests for covid19 and flu .They recommend the use of these type of tests in hospital settings .Now we have to wait and see whose test the French go for .
https://www.has-sante-fr/jcms/p_3213581/en/distinguer-la-grippe-de-la-covid-19-dans-quelles-situations-et-avec-quels-tests